1
|
Siedzielnik M, Pawłowska M, Daśko M, Kleinschmidt H, Dołęga A. Reactions of cobalt(ii) chloride and cobalt(ii) acetate with hemisalen-type ligands: ligand transformation, oxidation of cobalt and complex formation. Preliminary study on the cytotoxicity of Co(ii) and Co(iii) hemisalen complexes. RSC Adv 2023; 13:8830-8843. [PMID: 36936819 PMCID: PMC10018370 DOI: 10.1039/d2ra07089h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 03/08/2023] [Indexed: 03/18/2023] Open
Abstract
Several molecular cobalt(ii) complexes, one Co(ii) coordination polymer and one ionic cobalt(iii) complex with imine hemisalen ligands were synthesized. The hemisalen ligands were synthesized from o-vanillin (oVP) and diverse aminopyridines (compounds HL1-HL4) or aminophenol (compound HL5). It was observed that cobalt(ii) chloride in dry acetonitrile catalyzes a transformation of HL1 and HL3 instead of complex formation. The conversion of these imines proceeded via self-cyclization to N-2''-pyridyl-2,6-dioxo-9-aza-[c,g]di-2'-methoxybenzo nonan or its methyl derivative as the major product. The remaining reactions were performed using imines HL1-HL5 and cobalt(ii) acetate Co(Ac)2 in methanol or DMSO/acetonitrile resulting in forming a series of cobalt complexes. The following series of compounds was obtained: two similar tetrahedral molecular Co(ii) complexes [Co(L1)2] and [Co(L3)2], one trinuclear, mixed-ligand Co3(Ac)2(L4)2(oVP)2, one coordination polymer {Co(L2)2}∞ and finally one octahedral anionic Co(iii) complex [HNEt3][Co(L5)3]. The latter complex formed in a cobalt(ii) acetate reaction with a hemisalen HL5 derived from oVP and 2-aminophenol. The molecular structures of all compounds were confirmed by X-ray diffraction, and the cytotoxicity of Co(ii) and Co(iii) complexes towards cancer cell lines HCT116, HL-60 and normal cell line MRC-5 was studied.
Collapse
Affiliation(s)
- Magdalena Siedzielnik
- Department of Inorganic Chemistry, Chemical Faculty, Gdansk University of Technology Narutowicza 11/12 80-233 Gdansk Poland
| | - Monika Pawłowska
- Department of Pharmaceutical Technology and Biochemistry, Chemical Faculty, Gdansk University of Technology Narutowicza 11/12 80-233 Gdansk Poland
| | - Mateusz Daśko
- Department of Inorganic Chemistry, Chemical Faculty, Gdansk University of Technology Narutowicza 11/12 80-233 Gdansk Poland
| | - Hubert Kleinschmidt
- Department of Inorganic Chemistry, Chemical Faculty, Gdansk University of Technology Narutowicza 11/12 80-233 Gdansk Poland
| | - Anna Dołęga
- Department of Inorganic Chemistry, Chemical Faculty, Gdansk University of Technology Narutowicza 11/12 80-233 Gdansk Poland
| |
Collapse
|
2
|
Kumar Tarai S, Mandal S, Bhaduri R, Pan A, Biswas P, Bhattacharjee A, Moi SC. Bioactivity, molecular docking and anticancer behavior of pyrrolidine based Pt(II) complexes: Their kinetics, DNA and BSA binding study by spectroscopic methods. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2023; 287:122059. [PMID: 36410178 DOI: 10.1016/j.saa.2022.122059] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 09/29/2022] [Accepted: 10/26/2022] [Indexed: 06/16/2023]
Abstract
The complex [Pt(AEP)Cl2]; C-1 (where, AEP = 1-(2-Aminoethyl) pyrrolidine) and its hydrolyzed diaqua form cis-[Pt(AEP)(H2O)2]2+; C-2 were synthesized for their bioactivity and in vitro kinetic study with bioactive thiol group (-SH) containing ligands (like; L- cysteine and N-ac-L- cysteine) for their biological importance for 'drug reservoir' activity. The Thermal Gravimetric Analysis (TGA) was executed to confirm about the weight loss due to coordinated water molecules at high temperature range. At pH 4.0, the substitution behavior of C-2 with the thiols was studied in pseudo-first order reaction condition. The interaction mechanism of thiols with complex C-2 to their corresponding thiol substituted C-3 [Pt(AEP)(L-cys)] and C-4 [Pt(AEP)(N-ac-L-cys)] (where L-cys = L-cysteine and N-ac-L-cys = N-ac-L- cysteine) were proposed from their thermodynamical activation parameters (ΔH≠ and ΔS≠), which were obtained from Eyring equation. DNA and BSA binding activity of the complexes C-1 to C-4 were investigated by gel electrophoresis technique, spectroscopic titration and viscosity methods. The binding activity of the complexes with DNA and BSA was evaluated using a theoretical approach molecular docking study. The drug-like nature of the complexes is supported by the prediction of activity spectra for substance (PASS) from 2D structure of the Pt(II) complexes. Structural optimization, HOMO-LUMO energy calculation, Molecular electrostatic potential surface, NBO and TD-DFT calculation were executed by using density functional theory (DFT) with Gaussian 09 software package to pre-assessment of biological activity of the complexes. DFT-based descriptors were determined from the HOMO-LUMA energy to be related with the ability of binding affinity of Pt(II) complexes towards DNA and BSA to the formation of their corresponding adducts. The anticancer property of the design complexes were examined on HCT116 (colorectal carcinoma) cancer cell lines and as well as human normal cell NKE (Normal Kidney Epithelial) and compared with the recognised anticancer drug cisplatin. The Reactive Oxygen Species (ROS) production was assessed by DCFDA assay in presence of the Pt(II) complexes.
Collapse
Affiliation(s)
- Swarup Kumar Tarai
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur 713209, West Bengal, India
| | - Saikat Mandal
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur 713209, West Bengal, India
| | - Rituparna Bhaduri
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur 713209, West Bengal, India
| | - Angana Pan
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur 713209, West Bengal, India
| | - Pritam Biswas
- Department of Biotechnology, National Institute of Technology Durgapur, Durgapur 713209, West Bengal, India
| | - Ashish Bhattacharjee
- Department of Biotechnology, National Institute of Technology Durgapur, Durgapur 713209, West Bengal, India
| | - Sankar Ch Moi
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur 713209, West Bengal, India.
| |
Collapse
|
3
|
Mandal S, Tarai SK, Pan A, Bhaduri R, Biswas P, Moi SC. Cytotoxic effects of Pd(II) complexes on cancer and normal cells: Their DNA & BSA adduct formation and theoretical approaches. Bioorg Chem 2022; 128:106093. [PMID: 35985157 DOI: 10.1016/j.bioorg.2022.106093] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Revised: 07/29/2022] [Accepted: 08/09/2022] [Indexed: 12/12/2022]
Abstract
Herein, we report the synthesis and characterisation of a series of Pd(II) complexes: Pd(TEEDA)Cl2, C-1; [Pd(TEEDA)(OH2)2](NO3)2, C-2; [Pd(TEEDA)(l-cys)](NO3)2, C-3; [Pd(TEEDA)(NALC)], C-4; [Pd(TEEDA)(Meth)](NO3)2, C-5; and [Pd(TEEDA)(GSH)], C-6 (where TEEDA = N,N,N'-Triethylenediamine, l-cys = l-cysteine, NALC = N-acetyl-l-cysteine, Meth = dl-methionine and GSH = glutathione). UV-Vis spectroscopic characterisation was supported by TD-DFT theoretical simulation using Gaussian09 software. Different reactivity parameters were calculated from the energy difference between HOMO and LUMO of the complexes by DFT. The bonding mode of the labile ligands was confirmed by NBO analysis. Interaction of the complexes with DNA has been observed by gel electrophoresis experiment. DNA binding nature as well as binding constants of the complexes were measured with UV-Vis and fluorescence spectroscopic method. The binding nature of the complexes with DNA was confirmed by viscometric titration. Interaction of the complexes with BSA was investigated by UV-Vis and fluorescence titration method. Cytotoxic activity of the Pd(II) complexes was evaluated on A549 (lung carcinoma epithelial cells), HCT116(Colorectal Carcinoma) and HEK293 (Human embryonic kidney cells) cell lines. The ROS generation in the presence of the complexes was tested both on cancer cell lines A549 and HCT116 as well as human normal cell HEK293.
Collapse
Affiliation(s)
- Saikat Mandal
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur- 713209, West Bengal, India
| | - Swarup Kumar Tarai
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur- 713209, West Bengal, India
| | - Angana Pan
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur- 713209, West Bengal, India
| | - Rituparna Bhaduri
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur- 713209, West Bengal, India
| | - Pritam Biswas
- Department of Biotechnology, National Institute of Technology Durgapur, Durgapur- 713209, West Bengal, India
| | - Sankar Chandra Moi
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur- 713209, West Bengal, India.
| |
Collapse
|
4
|
The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer. Exp Cell Res 2022; 419:113276. [PMID: 35863454 DOI: 10.1016/j.yexcr.2022.113276] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 07/01/2022] [Accepted: 07/05/2022] [Indexed: 11/22/2022]
Abstract
Chemotherapy resistance limits the efficacy of cisplatin (DDP) when treating non-small cell lung cancer (NSCLC). Circular RNAs (circRNAs) confers a regulatory role in drug resistance. Innovatively, the regulatory role of circular RNA HIPK2 (circHIPK2) in DDP resistance was probed in the work. In this research, tumor tissues and matched normal tissues were obtained from 52 NSCLC patients, and the expressions of circHIPK2, miR-1249-3p and VEGFA in the tissues were detected by qPCR or Western Blot. Correlation analysis of circHIPK2 expression with survival prognosis and clinicopathological features was conducted. Parental NSCLC cell lines (A549, H460) and DDP-resistant cell lines (A549/DDP, H460/DDP) were selected, and the expression of circHIPK2, miR-1249-3p and VEGFA in the cells were detected. Cell IC50 value, proliferation, migration, invasion, apoptosis and angiogenesis were detected. Tumor xenografts were established to detect the role of circHIPK2 in vivo. The binding relationship between circHIPK2, miR-1249-3p and VEGFA was verified by dual luciferase reporter experiment, RNA pull down and RIP experiment. Our data showed that circHIPK2 and VEGFA were abnormally overexpressed and miR-1249-3p was underexpressed in DDP-resistant NSCLC tissues and cell lines. CircHIPK2 knockdown or miR-1249-3p upregulation inhibited DDP resistance, malignant behavior, and angiogenesis in NSCLC. CircHIPK2 by competitive absorption of miR-1249-3p mediated VEGFA. CircHIPK2 promoted the sensitivity of drug-resistant cells to DDP in NSCLC by regulating VEGFA. CircHIPK2 enhanced the growth of DDP-resistant NSCLC cells in vivo. In conclusion, circHIPK2 has the malignant property for angiogenesis and chemoresistance in NSCLC via the network of miR-1249-3p/VEGFA.
Collapse
|
5
|
Pietras P, Aulas A, Fay MM, Leśniczak-Staszak M, Sowiński M, Lyons SM, Szaflarski W, Ivanov P. Translation inhibition and suppression of stress granules formation by cisplatin. Biomed Pharmacother 2021; 145:112382. [PMID: 34864307 PMCID: PMC8782064 DOI: 10.1016/j.biopha.2021.112382] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Revised: 10/13/2021] [Accepted: 10/25/2021] [Indexed: 12/24/2022] Open
Abstract
Platinum-based antineoplastic drugs, such as cisplatin, are commonly used to induce tumor cell death. Cisplatin is believed to induce apoptosis as a result of cisplatin-DNA adducts that inhibit DNA and RNA synthesis. Although idea that DNA damage underlines anti-proliferative effects of cisplatin is dominant in cancer research, there is a poor correlation between the degree of the cell sensitivity to cisplatin and the extent of DNA platination. Here, we examined possible effects of cisplatin on post-transcriptional gene regulation that may contribute to cisplatin-mediated cytotoxicity. We show that cisplatin suppresses formation of stress granules (SGs), pro-survival RNA granules with multiple roles in cellular metabolism. Mechanistically, cisplatin inhibits cellular translation to promote disassembly of polysomes and aggregation of ribosomal subunits. As SGs are in equilibrium with polysomes, cisplatin-induced shift towards ribosomal aggregation suppresses SG formation. Our data uncover previously unknown effects of cisplatin on RNA metabolism.
Collapse
Affiliation(s)
- Paulina Pietras
- Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland
| | - Anaïs Aulas
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Marta M Fay
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Marta Leśniczak-Staszak
- Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland
| | - Mateusz Sowiński
- Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland
| | - Shawn M Lyons
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Witold Szaflarski
- Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
| | - Pavel Ivanov
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
| |
Collapse
|
6
|
Bhaduri R, Mukherjee S, Mitra I, Ghosh S, Chatterji U, Dodda SR, Moi SC. Anticancer activity and cell death mechanism of Pt(II) complexes: Their in vitro bio-transformation to Pt(II)-DNA adduct formation and BSA binding study by spectroscopic method. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2021; 262:120096. [PMID: 34214741 DOI: 10.1016/j.saa.2021.120096] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/21/2021] [Revised: 06/10/2021] [Accepted: 06/17/2021] [Indexed: 06/13/2023]
Abstract
Pt(II) complex cis-[Pt(PEA)(OH2)2] X2, C-2 (where, PEA = 2-Pyridylethylamine and X = ClO4- or NO3-) was synthesized by hydrolysis of cis-[Pt(PEA)Cl2] C-1. Glutathione (GSH) and DL-penicilamine (DL-pen) substituted complexes cis-[Pt(PEA)(GSH)],C-3 and cis-[Pt(PEA)DL-pen)]X C-4 were synthesized and characterized by spectroscopic methods. Kinetic studies were traced on complex C-2 with the thiols, GSH and DL-pen. Pt(II)-Sulfur adduct formation mechanisms of the substituted products C-3 and C-4 were established from the kinetic investigation. At pH 4.0, C-2 - thiols interactions follow two consecutive steps: the first step is dependent, and the second is independent of [thiol]. The association equilibrium constant (KE), substitution rate constants for both steps (k1 & k2), and activation parameters (ΔH‡ and ΔS‡) have been assessed to propose the mechanism. Agarose gel electrophoresis mobilization pattern of DNA with complexes was performed to visualize the interaction nature. CT-DNA and BSA binding activities of the complexes have been executed by electronic, fluorescence spectroscopy, and viscometric titration methods. Evaluation of thermodynamic parameters (ΔH0, ΔS0, and ΔG0) from BSA binding constants was executed to propose the driving forces of interaction between these species. A molecular docking study was performed to evaluate the binding mode of complexes with BDNA strands. Anticancer activity of the complexes C-1 to C-4 was explored on both A549 and HEp-2 cell lines, compared with approved anticancer drugs cisplatin, carboplatin, and oxaliplatin. All these complexes were tested by NBT assay on normal cell line skeletal muscle cells (L6 myotubes) to observe the adverse effects compared to recognized anticancer medications. The ultimate aim is to explore the role of anticancer agents on cell death mechanism, which has been performed by flow-cytometer on HEp-2 cell lines.
Collapse
Affiliation(s)
- Rituparna Bhaduri
- Department of Chemistry, National Institute of Technology Durgapur, M.G. Avenue, Durgapur 713209, West Bengal, India
| | - Subhajit Mukherjee
- Department of Chemistry, National Institute of Technology Durgapur, M.G. Avenue, Durgapur 713209, West Bengal, India
| | - Ishani Mitra
- Department of Chemistry, National Institute of Technology Durgapur, M.G. Avenue, Durgapur 713209, West Bengal, India
| | - Subarna Ghosh
- Cancer Research Laboratory, Department of Zoology, University of Calcutta, Kolkata 700019, W.B., India
| | - Urmi Chatterji
- Cancer Research Laboratory, Department of Zoology, University of Calcutta, Kolkata 700019, W.B., India
| | - Subba Reddy Dodda
- Department of Biotechnology, National Institute of Technology Durgapur, M.G. Avenue, Durgapur 713209, WB, India
| | - Sankar Ch Moi
- Department of Chemistry, National Institute of Technology Durgapur, M.G. Avenue, Durgapur 713209, West Bengal, India.
| |
Collapse
|
7
|
Mandal S, Reddy B. VP, Mitra I, Mukherjee S, Tarai SK, Bhaduri R, Pan A, Bose K. JC, Ghosh GK, Moi SC. Anticancer activity and biomolecular interaction of Pt(II) complexes: Their synthesis, characterisation and DFT study. Appl Organomet Chem 2021. [DOI: 10.1002/aoc.6506] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
- Saikat Mandal
- Department of Chemistry National Institute of Technology Durgapur Durgapur India
| | - Venkata P. Reddy B.
- Department of Chemistry National Institute of Technology Durgapur Durgapur India
| | - Ishani Mitra
- Department of Chemistry National Institute of Technology Durgapur Durgapur India
| | - Subhajit Mukherjee
- Department of Chemistry National Institute of Technology Durgapur Durgapur India
| | - Swarup Kumar Tarai
- Department of Chemistry National Institute of Technology Durgapur Durgapur India
| | - Rituparna Bhaduri
- Department of Chemistry National Institute of Technology Durgapur Durgapur India
| | - Angana Pan
- Department of Chemistry National Institute of Technology Durgapur Durgapur India
| | | | - Goutam Kr. Ghosh
- Department of Chemistry National Institute of Technology Durgapur Durgapur India
| | - Sankar Chandra Moi
- Department of Chemistry National Institute of Technology Durgapur Durgapur India
| |
Collapse
|
8
|
Ojha R, Mason D, Forsyth CM, Deacon GB, Junk PC, Bond AM. Diverse and unexpected outcomes from oxidation of the platinum(II) anticancer agent [Pt{(p-BrC 6F 4)NCH 2CH 2NEt 2}Cl(py)] by hydrogen peroxide. J Inorg Biochem 2021; 218:111360. [PMID: 33711633 DOI: 10.1016/j.jinorgbio.2021.111360] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2020] [Revised: 01/17/2021] [Accepted: 01/17/2021] [Indexed: 12/18/2022]
Abstract
Oxidation of the anti-tumour agent [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)], 1 (py = pyridine) with hydrogen peroxide under a variety of conditions yields a range of organoenamineamidoplatinum(II) compounds [Pt{(p-BrC6F4)NCH=C(X)NEt2}Cl(py)] (X = H, Cl, Br) as well as species with shared occupancy involving H, Cl and Br. Thus, oxidation of the -CH2-CH2- backbone (dehydrogenation) occurs, often accompanied by substitution. Oxidation of 1 with H2O2 in acetone yielded 1:1 co-crystallized [Pt{(p-BrC6F4)NCH=CHNEt2}Cl(py)], 1H and [Pt{(p-BrC6F4)NCH=C(Cl)NEt2}Cl(py)], 1Cl. The former was obtained pure in low yield from the oxidation of 1 with (NH4)2[Ce(NO3)6] in acetone, and the latter was obtained from 1 and H2O2 in CH2Cl2 at near reflux. From the latter reaction under vigorous refluxing [Pt{(p-BrC6F4)NCH=C(Br)NEt2}Cl(py)], 1Br was isolated. In refluxing acetonitrile, oxidation of 1 with H2O2 yielded [Pt{(p-BrC6F4)NCH=C(H0.25Br0.75)NEt2}Cl(py)], 1H0.25Br0.75, in which the alkene is mainly substituted by Br in a dual occupancy. Treatment of 1 with H2O2 and tetrabutylammonium hydroxide in acetone at room temperature formed [Pt{(p-HC6F4)NCH2CH2NEt2}Cl(py)], 2. Oxidation of [Pt{(p-HC6F4)NCH2CH2NEt2}Br(py)], 3 with H2O2 in boiling acetonitrile gave the ligand oxidation product [Pt{(p-HC6F4)NCH=C(Br)NEt2}Br(py)], 3Br. All major products were identified by X-ray crystallography as well as by 1H and 19F NMR spectra. In cases of mixed crystals or dual occupancy compounds, the 19F and 1H NMR spectra showed dissociation into the components in the solution in the same proportions as in isolated crystalline material.
Collapse
Affiliation(s)
- Ruchika Ojha
- School of Chemistry, Monash University, Clayton 3800, VIC, Australia
| | - Dayna Mason
- School of Chemistry, Monash University, Clayton 3800, VIC, Australia
| | - Craig M Forsyth
- School of Chemistry, Monash University, Clayton 3800, VIC, Australia
| | - Glen B Deacon
- School of Chemistry, Monash University, Clayton 3800, VIC, Australia.
| | - Peter C Junk
- College of Science & Engineering, James Cook University, Townsville, Qld 4811, Australia.
| | - Alan M Bond
- School of Chemistry, Monash University, Clayton 3800, VIC, Australia.
| |
Collapse
|
9
|
Pan A, Mitra I, Mukherjee S, Ghosh S, Chatterji U, Moi SC. Development of Anticancer Activity of the Pt(II) Complex with N-Heterocyclic Amine: Its In Vitro Pharmacokinetics with Thiol and Thio-Ethers, DNA and BSA Binding, and Cell Cycle Arrest. ACS APPLIED BIO MATERIALS 2021. [DOI: 10.1021/acsabm.0c01374] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Angana Pan
- Department of Chemistry, National Institute of Technology Durgapur, M. G. Avenue, Durgapur-713209, West Bengal, India
| | - Ishani Mitra
- Department of Chemistry, National Institute of Technology Durgapur, M. G. Avenue, Durgapur-713209, West Bengal, India
| | - Subhajit Mukherjee
- Department of Chemistry, National Institute of Technology Durgapur, M. G. Avenue, Durgapur-713209, West Bengal, India
| | - Subarna Ghosh
- Cancer Research Laboratory, Department of Zoology, University of Calcutta, Kolkata 700019, West Bengal, India
| | - Urmi Chatterji
- Cancer Research Laboratory, Department of Zoology, University of Calcutta, Kolkata 700019, West Bengal, India
| | - Sankar Chandra Moi
- Department of Chemistry, National Institute of Technology Durgapur, M. G. Avenue, Durgapur-713209, West Bengal, India
| |
Collapse
|
10
|
Zhang J, Hua X, Qi N, Han G, Yu J, Yu Y, Wei X, Li H, Chen X, Leng C, Liu Q, Lu Y, Li Y. MiR-27b suppresses epithelial-mesenchymal transition and chemoresistance in lung cancer by targeting Snail1. Life Sci 2019; 254:117238. [PMID: 31887300 DOI: 10.1016/j.lfs.2019.117238] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 12/16/2019] [Accepted: 12/25/2019] [Indexed: 02/07/2023]
Abstract
HEADING AIMS MicroRNA-27b (miR-27b) has been shown to play a role in the progression of many different forms of cancer, but its specific relevance in the context of non-small cell lung cancer (NSCLC) remains uncertain. As such, this study sought to explore the role of miR-27b in NSCLC and the mechanisms whereby it functions. MATERIALS AND METHODS We quantified miR-27b and target gene expression via quantitative real-time PCR (RT-qPCR).We then used functional including proliferation assays, migration assay, flow cytometry, and western blotting to explore the mechanisms whereby miR-27b functions in vitro and in vivo. We additionally confirmed miR-27b target genes via luciferase reporter assay. KEY FINDINGS We observed a marked decrease in miR-27b expression in NSCLC patient samples relative to paracancerous control tissues. We further found that altering miR-27b expression levels in vitro affected NSCLC tumor cell migration, proliferation, and ability to undergo epithelial-mesenchymal transition. Through the use of target prediction algorithms we identified Snail to be a miR-27b target protein that was suppressed when this miRNA was highlight expressed. Lastly, we found miR-27b expression to increase NSCLC cell sensitivity to cisplatin through its ability to target Snail. SIGNIFICANCE Our results clearly demonstrate that miR-27b can suppress NSCLC tumor development and progression, highlighting this miR-27b/Snail1 axis as putative target for the therapeutic treatment of NSCLC.
Collapse
Affiliation(s)
- Jun Zhang
- Department of Endoscopic Diagnosis and Treatment Center, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China
| | - Xionghuai Hua
- Department of Endoscopic Diagnosis and Treatment Center, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China
| | - Na Qi
- Medical Genetic Institute, Henan Provincial People's Hospital, Henan, China
| | - Guangsen Han
- Department of general surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China
| | - Juan Yu
- Department of Endoscopic Diagnosis and Treatment Center, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China
| | - Yongkui Yu
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China
| | - Xiufeng Wei
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China
| | - Haomiao Li
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China
| | - Xiankai Chen
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China
| | - Changsen Leng
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China
| | - Qi Liu
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China
| | - Yingmin Lu
- Department of Thoracic Surgery, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Henan, China
| | - Yin Li
- Department of Endoscopic Diagnosis and Treatment Center, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan, China.
| |
Collapse
|
11
|
Kato R, Sato T, Iwamoto A, Yamazaki T, Nakashiro S, Yoshikai S, Fujimoto A, Imano H, Ijiri Y, Mino Y, Chikuma M, Tanaka K, Hayashi T. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albuminin vivorats andin vitrostudy using inductively coupled plasma-mass spectrometory. Biopharm Drug Dispos 2019; 40:242-249. [DOI: 10.1002/bdd.2197] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Revised: 04/12/2019] [Accepted: 06/02/2019] [Indexed: 11/09/2022]
Affiliation(s)
- Ryuji Kato
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Takaji Sato
- Department of Bio-Analytical Chemistry; Osaka University of Pharmaceutical Sciences; Takatsuki 569-1094 Japan
- Education and Research Center for Fundamental Pharmaceutical Sciences; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Asuka Iwamoto
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Taku Yamazaki
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Satomi Nakashiro
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Shoichi Yoshikai
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Ayumi Fujimoto
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | - Hideki Imano
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| | | | - Yoshiki Mino
- Department of Bio-Analytical Chemistry; Osaka University of Pharmaceutical Sciences; Takatsuki 569-1094 Japan
| | - Masahiko Chikuma
- Department of Bio-Analytical Chemistry; Osaka University of Pharmaceutical Sciences; Takatsuki 569-1094 Japan
| | - Kazuhiko Tanaka
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
- Shirasagi Hospital; 7-11-23 Kumata Higashisumiyosi-ku, Osaka 546-0002 Japan
| | - Tetsuya Hayashi
- Department of Cardiovascular Pharmacotherapy and Toxicology; Osaka University of Pharmaceutical Sciences; 4-20-1 Nasahara Takatsuki, Osaka 569-1094 Japan
| |
Collapse
|
12
|
Xing S, Qu Y, Li C, Huang A, Tong S, Wu C, Fan K. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT. J Cell Physiol 2019; 234:22657-22665. [PMID: 31111480 DOI: 10.1002/jcp.28832] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2019] [Accepted: 04/29/2019] [Indexed: 01/12/2023]
Abstract
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death worldwide. As a platinum-based chemotherapeutic drug, cisplatin has been used in the NSCLC treatment for over 30 years, and its effects are impaired by drug resistance. This study aimed to investigate the potential role of lncRNA-AC078883.3 in the development of chemoresistance against cisplatin. Real-time PCR, Western blot analysis, Immunohistochemistry (IHC) assay, bioinformatic analysis, and luciferase assay were collaboratively used to establish the lncRNA-AC078883.3/miR-19a/PTEN/AKT pathway. Also, the effect of cisplatin on cell proliferation was observed via an MTT assay. Furthermore, Cox regression and Kaplan-Meier analyses were used to study whether lncRNA-AC078883.3 is involved in the survival of NSCLC. Compared with the Cisplatin-Sensitive group, the Cisplatin-Resistance group exhibited lower levels of lncRNA-AC078883.3 and PTEN and higher levels of miR-19a and p-Akt. The growth rate of A549 and H460 cells and the IC 50 of DPP in the Cisplatin-Resistance group were higher than those in the Cisplatin-S group. miR-19a contains a putative binding site of lncRNA-AC078883.3, which enabled the luciferase activity of wild-type lncRNA-AC078883.3 to be reduced by miR-19a. In addition, by directly targeting PTEN 3'-untranslated region (UTR), miR-19a repressed the luciferase activity of wild-type PTEN 3'-UTR. The median OS of patients with reduced lncRNA-AC078883.3 expression was longer than that of patients with higher lncRNA-AC078883.3 expression. Finally, compared with low lncRNA-AC078883.3-expression patients, the high lncRNA-AC078883.3-expression patients were associated with lower miR-19a expression and higher PTEN expression. Therefore, we suggested for the first time that the low expression of lncRNA-AC078883.3 contributed to the development of chemoresistance against cisplatin.
Collapse
Affiliation(s)
- Shijie Xing
- Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yue Qu
- Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Chaoyi Li
- Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Ai Huang
- Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Song Tong
- Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Chuangyan Wu
- Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Kai Fan
- Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
13
|
Mahata S, Mukherjee S, Tarai SK, Pan A, Mitra I, Pal S, Maitra S, Moi SC. Synthesis and characterization of Pt(ii)-based potent anticancer agents with minimum normal cell toxicity: their bio-activity and DNA-binding properties. NEW J CHEM 2019. [DOI: 10.1039/c9nj03108a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The Cis-Pt(ii)-dichloro complex and its different intercellular derivates show good DNA-binding, comparable anticancer properties and less normal cell toxicity than cisplatin, and initiates cell death through apoptosis.
Collapse
Affiliation(s)
- Sujay Mahata
- Department of Chemistry
- National Institute of Technology Durgapur
- Durgapur-713209
- India
| | - Subhajit Mukherjee
- Department of Chemistry
- National Institute of Technology Durgapur
- Durgapur-713209
- India
| | - Swarup Kumar Tarai
- Department of Chemistry
- National Institute of Technology Durgapur
- Durgapur-713209
- India
| | - Angana Pan
- Department of Chemistry
- National Institute of Technology Durgapur
- Durgapur-713209
- India
| | - Ishani Mitra
- Department of Chemistry
- National Institute of Technology Durgapur
- Durgapur-713209
- India
| | - Soumojit Pal
- Department of Zoology
- Visva-Bharati University
- Santinikatan
- India
| | - Sudipta Maitra
- Department of Zoology
- Visva-Bharati University
- Santinikatan
- India
| | - Sankar Ch. Moi
- Department of Chemistry
- National Institute of Technology Durgapur
- Durgapur-713209
- India
| |
Collapse
|
14
|
Song X, Kong F, Zong Z, Ren M, Meng Q, Li Y, Sun Z. miR-124 and miR-142 enhance cisplatin sensitivity of non-small cell lung cancer cells through repressing autophagy via directly targeting SIRT1. RSC Adv 2019; 9:5234-5243. [PMID: 35514612 PMCID: PMC9060797 DOI: 10.1039/c8ra09914f] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2018] [Accepted: 02/04/2019] [Indexed: 12/18/2022] Open
Abstract
Background: Drug resistance is a major obstacle in the treatment of non-small cell lung cancer (NSCLC). Recently, miRNAs are reported to be involved in the drug resistance of NSCLC. The roles of miR-124 and miR-142 in the multidrug resistance of NSCLC cells have been reported. However, the underlying mechanism by which miR-124 and miR-142 regulate resistance to cisplatin (CDDP) remains unknown. Methods: The expressions of miR-124, miR-142 and sirtuin 1 (SIRT1) in CDDP-sensitive and CDDP-resistant NSCLC tissues and cells were detected by qRT-PCR and western blot. IC50 value and cell proliferation were determined by MTT assay. Apoptosis was assessed by flow cytometry analysis. Autophagy was evaluated by western blot analysis of the protein levels of LC3-I, LC3-II and p62, and FITC-LC3 punctate formation assay. The interaction between miR-124 or miR-142 and SIRT1 was determined by luciferase reporter, RNA immunoprecipitation (RIP) and western blot assays. A tumor xenograft was performed to further validate the role of miR-124 and miR-142 in the sensitivity of CDDP-resistant NSCLC to cisplatin. Results: miR-124 and miR-142 were downregulated, while SIRT1 was upregulated in CDDP-resistant NSCLC tissues and cells compared to CDDP-sensitive groups. Functionally, overexpression of miR-124 and miR-142 or SIRT1 silencing enhanced the CDDP sensitivity of H1299/CDDP cells via suppressing autophagy, as evidenced by the reduced LC3-II/LC3-I radio, elevated p62 protein, and suppressed FITC-LC3 punctate formation in H1299/CDDP cells. miR-124 and miR-142 were demonstrated to co-target SIRT1. Re-expression of SIRT1 overturned miR-124 and miR-142-mediated chemosensitivity in H1299/CDDP cells via triggering autophagy. Conclusion: miR-124 and miR-142 enhance the cytotoxic effect of CDDP through repressing autophagy via targeting SIRT1 in CDDP-resistant NSCLC cells. Drug resistance is a major obstacle in the treatment of non-small cell lung cancer (NSCLC).![]()
Collapse
Affiliation(s)
- Xiang Song
- Department of Thoracic Surgery
- Cangzhou Central Hospital
- Cangzhou 061000
- China
| | - Fanyi Kong
- Department of Thoracic Surgery
- Cangzhou Central Hospital
- Cangzhou 061000
- China
| | - Zhenfeng Zong
- Department of Thoracic Surgery
- Cangzhou Central Hospital
- Cangzhou 061000
- China
| | - Mingming Ren
- Department of Thoracic Surgery
- Cangzhou Central Hospital
- Cangzhou 061000
- China
| | - Qingjun Meng
- Department of Thoracic Surgery
- Cangzhou Central Hospital
- Cangzhou 061000
- China
| | - Yanguang Li
- Department of Thoracic Surgery
- Cangzhou Central Hospital
- Cangzhou 061000
- China
| | - Zhen Sun
- Department of Thoracic Surgery
- Cangzhou Central Hospital
- Cangzhou 061000
- China
| |
Collapse
|
15
|
Jin D, Wu Y, Shao C, Gao Y, Wang D, Guo J. Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway. Oncol Rep 2018; 40:609-620. [PMID: 29901163 PMCID: PMC6072289 DOI: 10.3892/or.2018.6486] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Accepted: 05/25/2018] [Indexed: 02/06/2023] Open
Abstract
Non-small cell lung cancer (NSCLC) accounts for >80% of all lung cancer cases, which are the leading cause of cancer-related mortality worldwide. The clinical efficacy of available therapies for NSCLC is often limited due to the development of resistance to anticancer drugs, particularly to cisplatin (DDP). Norcantharidin (NCTD) is a traditional Chinese medicine used in the treatment of many types of cancer, to which patients do not develop resistance. The aim of the present study was to examine the potential synergistic effects of NCTD and DPP on the viability of the the DDP-resistant NSCLC cell line, A549/DDP. We further explored the potential underlying mechanisms by examining the expression of the oncogene, Yes-associated protein 1 (YAP), whose activation was recently found to be associated with drug resistance. We further examined a series of human lung cancer cell lines and tissues from patients with lung cancer, which revealed that YAP activation contributed to lung cancer initiation, progression and metastasis, and was associated with a poor prognosis, and confering resistance against targeted therapies. Moreover, YAP expression was evaluated in the A549/DDP cells treated with NCTD, DDP, or both drugs. The combined treatment significantly sensitized the A549/DDP cells to DDP-induced growth inhibition by reducing YAP promoter activity (based on transcriptional expression) and the expression of its target genes, connective tissue growth factor (CTGF) and cysteine rich angiogenic inducer 61 (CYR61). Furthermore, compared to the individual treatments, combined treatment increased cell apoptosis and senescence, and decreased epithelial-to-mesenchymal transition and the cell migratory and invasive ability. On the whole, our data indicate that the application of NCTD with reverses DDP resistance and thus, this combined treatment may have promising prospects for use in improving the outcome of patients with NSCLC.
Collapse
Affiliation(s)
- Dan Jin
- Department of Pain Medicine, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China
| | - Yan Wu
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China
| | - Cuijie Shao
- Department of Pain Medicine, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China
| | - Yong Gao
- Department of Pain Medicine, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China
| | - Deqiang Wang
- Department of Pain Medicine, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China
| | - Jiwei Guo
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China
| |
Collapse
|
16
|
Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells. TUMORI JOURNAL 2018; 104:338-343. [PMID: 28885675 DOI: 10.5301/tj.5000656] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Background: Pleural effusion is one of the complications of human non-small cell lung cancer (NSCLC). High mobility group box-1 protein (HMGB1) correlates highly with invasion and metastasis in multiple tumors. The aim of this study was to explore the clinical value of HMGB1 in NSCLC patients, and to investigate the role of HMGB1 in the development of pleural effusion. In addition, we also investigated the regulatory role of HMGB1 in the sensitivity of NSCLC cells to cisplatin. Methods: 46 NSCLC malignant pleural effusion (MPE) and 31 benign pleural effusion samples were quantitatively analyzed with Enzyme-Linked Immunosorbent Assay (ELISA) for cytokines, such as IL-1beta, IL-6, IL-8 and HMGB1. The HMGB1 expression in NSCLC tissues was examined with RT-qPCR and western blotting methods. Then the influence by HMGB1 on the chemosensitivity of lung cancer A549 cells was examined with MTT assay and colony forming assay for the A549 cells post the treatment with cisplatin or (and) HMGB1. Results: The results demonstrated that HMGB1 was up-regulated in the pleural effusion of NSCLC patients, along with the up-regulated levels of proinflammatory cytokines such as IL-6 and IL-8. And the up-regulation of HMGB1 was confirmed at both the mRNA and protein levels in the NSCLC tissues. Recombinant HMGB1 reduced the sensitivity of A549 cells to cisplatin in vitro. Conclusions: In conclusion, HMGB1 was up-regulated in the pleural effusion and tumor tissues of NSCLC patients. HMGB1 reduced the sensitivity of NSCLC A549 cells to cisplatin in vitro.
Collapse
|
17
|
Mukherjee S, Mitra I, Reddy B. VP, Fouzder C, Mukherjee S, Ghosh S, Chatterji U, Moi SC. Effect of Pt(II) complexes on cancer and normal cells compared to clinically used anticancer drugs: Cell cycle analysis, apoptosis and DNA/BSA binding study. J Mol Liq 2017. [DOI: 10.1016/j.molliq.2017.09.104] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
18
|
Li C, Sun L, Jiang R, Wang P, Xue H, Zhan Y, Gai X. Downregulation of FOXP3 inhibits cell proliferation and enhances chemosensitivity to cisplatin in human lung adenocarcinoma. Pathol Res Pract 2017; 213:1251-1256. [PMID: 28935177 DOI: 10.1016/j.prp.2017.09.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 08/12/2017] [Accepted: 09/05/2017] [Indexed: 01/09/2023]
Abstract
Our study aimed to investigate the biological role of FOXP3 expression in human lung adenocarcinoma (LAD) tissues and evaluate its involvement in cell proliferation and chemosensitivity to cisplatin in LAD cells. Paraffin-embedded tissues from 50 LAD patients were collected to detect FOXP3 and Ki-67 expression using immunohistochemistry (IHC). Downregulation of FOXP3 in A549 cells was performed using siRNA transfection. Real-time PCR or western blot assay was performed to analyze FOXP3 expression in A549 cells. Cell proliferation and cisplatin cytotoxicity test were assessed by CCK-8 assay. The expression of FOXP3 was significantly associated with lymph node metastasis and TNM stage of LAD patients. The FOXP3 expression was positively correlated with Ki-67 labelling index(LI)in LAD tissues. The downregulated expression of FOXP3 by siRNA transfection significantly inhibited cell proliferation and enhanced chemosensitivity to cisplatin in A549 cells. The expression of FOXP3 was significantly upregulated following cisplatin treatment in A549 cells. Our study indicates that FOXP3 may potentially be a novel molecular target in combating drug resistance in the chemotherapy of LAD.
Collapse
Affiliation(s)
- Chun Li
- Department of Immunology, School of Basic Medical Sciences, Beihua University, Jilin, Jilin 132013, People's Republic of China
| | - Liwei Sun
- Jilin Technology Innovation Center for Chinese Medicine Biotechnology, College of Biology and Chemistry, Beihua University, Jilin, Jilin 132013, People's Republic of China
| | - Rui Jiang
- Jilin Technology Innovation Center for Chinese Medicine Biotechnology, College of Biology and Chemistry, Beihua University, Jilin, Jilin 132013, People's Republic of China
| | - Peng Wang
- Department of Immunology, School of Basic Medical Sciences, Beihua University, Jilin, Jilin 132013, People's Republic of China
| | - Haogang Xue
- Department of Surgery, Affiliated Hospital of Beihua University, Jilin, Jilin 132013, People's Republic of China
| | - Yudong Zhan
- Department of Immunology, School of Basic Medical Sciences, Beihua University, Jilin, Jilin 132013, People's Republic of China
| | - Xiaodong Gai
- Department of Immunology, School of Basic Medical Sciences, Beihua University, Jilin, Jilin 132013, People's Republic of China.
| |
Collapse
|
19
|
Shi L, Xu Z, Wu G, Chen X, Huang Y, Wang Y, Jiang W, Ke B. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. BMC Cancer 2017; 17:138. [PMID: 28202053 PMCID: PMC5312565 DOI: 10.1186/s12885-017-3132-9] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2016] [Accepted: 02/09/2017] [Indexed: 11/17/2022] Open
Abstract
Background Cisplatin (DDP)-based chemotherapy is the common first-line therapy for lung cancer. However, their efficacy is often limited by primary drug resistance and/or acquired drug resistance. The aim of this study was to investigate the function of miRNA-146a (miR-146a) in DDP-resistant non-small cell lung cancer (NSCLC), as well as the underlying mechanisms. Methods The effect of overexpression of miR-146a and/or knockdown of cyclin J (CCNJ) in A549/DDP and SPC-A1/DDP cells were investigated as follows. The cellular sensitivity to DDP, cell apoptosis, cell cycle and cell mobility were detected by CCK-8, flow cytometry, hoechst staining and cell invasion/migration assay, respectively. The effects of miR-146a overexpression in NSCLC resistant cells were further analyzed in a nude mouse xenograft model. Results Overexpression of miR-146a and/or knockdown of CCNJ significantly increased the sensitivity to DDP in A549/DDP and SPC-A1/DDP cells compared to NC group via arresting cell cycle, enhancing cell apoptosis, inhibiting cell viability and motility in vitro and in vivo. Furthermore, miR-146a could specially degrade the mRNA of CCNJ, as examined by dual luciferase report assay. Conclusion The study indicates a crucial role of miR-146a in the development of acquired drug resistance to DDP in NSCLC cells. Further understanding of miR-146a mediated crosstalk networks may promote the clinical use of miR-146a analogue in NSCLC therapy.
Collapse
Affiliation(s)
- Lin Shi
- Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510282, People's Republic of China
| | - Zhaozhong Xu
- Department of Emergency, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510282, People's Republic of China
| | - Gang Wu
- Department of Cancer Center, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510282, People's Republic of China
| | - Xiaoting Chen
- Department of Cancer Center, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510282, People's Republic of China
| | - Yuanyuan Huang
- Department of VIP & Traditional Chinese Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China
| | - Yanjing Wang
- Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510282, People's Republic of China
| | - Weiqiang Jiang
- Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510282, People's Republic of China
| | - Bin Ke
- Department of Traditional Chinese Medicine, The First Affiliated Hospital of Sun Yet-sen University, 58 Second Zhongshan Road, Guangzhou, Guangdong, 510080, People's Republic of China.
| |
Collapse
|
20
|
Kato R, Sato T, Kanamori M, Miyake M, Fujimoto A, Ogawa K, Kobata D, Fujikawa T, Wada Y, Mitsuishi R, Takahashi K, Imano H, Ijiri Y, Mino Y, Chikuma M, Tanaka K, Hayashi T. A Novel Analytical Method of Cisplatin Using the HPLC with a Naphthylethyl Group Bonded with Silica Gel (πNAP) Column. Biol Pharm Bull 2017; 40:290-296. [DOI: 10.1248/bpb.b16-00760] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Ryuji Kato
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Takaji Sato
- Laboratory of Bio-Analytical Chemistry, Osaka University of Pharmaceutical Sciences
| | - Michiko Kanamori
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Mizuho Miyake
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Ayumi Fujimoto
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Kyohei Ogawa
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Daiki Kobata
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Tomoya Fujikawa
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Yukari Wada
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Rintaro Mitsuishi
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Kodai Takahashi
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Hideki Imano
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Yoshio Ijiri
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| | - Yoshiki Mino
- Laboratory of Bio-Analytical Chemistry, Osaka University of Pharmaceutical Sciences
| | - Masahiko Chikuma
- Laboratory of Bio-Analytical Chemistry, Osaka University of Pharmaceutical Sciences
| | | | - Tetsuya Hayashi
- Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences
| |
Collapse
|
21
|
Cytotoxic, DNA binding and drug reservoir property of Pt(II)–sulfur complexes: In-vitro kinetics, mechanism with bio-relevant molecules in aqueous medium and a theoretical approach. Polyhedron 2016. [DOI: 10.1016/j.poly.2016.08.024] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
22
|
Li W, Wang W, Ding M, Zheng X, Ma S, Wang X. MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin. Cancer Cell Int 2016; 16:30. [PMID: 27073334 PMCID: PMC4828824 DOI: 10.1186/s12935-016-0305-6] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Accepted: 04/05/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Cisplatin (DDP)-based chemotherapy is the mainstay of first-line therapy for lung cancer. However, their efficacy is often limited by the existence or development of chemoresistance. The aim of this study was to find and investigate the function of miRNAs in cisplatin (DDP)-resistant non-small cell lung cancer (NSCLC) A549 cell. METHODS Quantitative real-time PCR assay was employed to compare the differences of miRNA expression in both cisplatin-resistant A549 (A549/DDP) cell and the parental A549 cell. The dysregulated miRNAs were then corrected by transfecting oligonucleotides into A549/DDP cells. The cellular sensitivity to cisplatin, cell apoptosis and migration were conducted by MTT, flow cytometry and cell wound healing assay, respectively. RESULTS Both miR-589 and miR-1244 were significantly down-regulated in A549/DDP cell compared to the parental A549, while the expression of miR-182 and miR-224 were increased in A549/DDP cell (P < 0.05). Importantly, transfection of the cisplatin-resistant cells with either miR-589 or miR-1244 resulted in an increased sensitivity to cisplatin, indicating that the dysregulated miRNA may play an important role in chemotherapy resistance in cancer cell. The rescued expression of miRNA also reduced cell invasion and increased apoptosis of A549/DDP cell. CONCLUSION The study indicates a crucial role of miR-1244 in the progress of cisplatin resistance of A549. Further understanding of miR-1244-mediated signaling pathways may promote the clinical use of miR-1244 in lung cancer therapy.
Collapse
Affiliation(s)
- Weili Li
- Center for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China.,Institute of Lung Cancer, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China
| | - Wenzhe Wang
- Center for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China.,Institute of Lung Cancer, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China
| | - Mingjian Ding
- Center for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China.,Institute of Lung Cancer, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China
| | - Xiaoliang Zheng
- Center for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China.,Institute of Lung Cancer, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China
| | - Shenglin Ma
- Department of Radiation Oncology, Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, Zhejiang People's Republic of China.,Institute of Lung Cancer, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China
| | - Xiaoju Wang
- Center for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China.,Institute of Lung Cancer, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang People's Republic of China
| |
Collapse
|
23
|
Ojha R, Nafady A, Shiddiky MJA, Mason D, Boas JF, Torriero AAJ, Bond AM, Deacon GB, Junk PC. Conditions Favoring the Formation of Monomeric PtIIIDerivatives in the Electrochemical Oxidation oftrans-[PtII{(p-BrC6F4)NCH2CH2NEt2}Cl(py)]. ChemElectroChem 2015. [DOI: 10.1002/celc.201402447] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
24
|
Mukherjee S, Reddy B. VP, Mitra I, Saha R, K. JCB, Reddy Dodda S, Linert W, Moi SC. In vitro model reaction of sulfur containing bio-relevant ligands with Pt(ii) complex: kinetics, mechanism, bioactivity and computational studies. RSC Adv 2015. [DOI: 10.1039/c5ra15740d] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
In vitrodrug reservoir model reactions of thiols with novel Pt(ii) complex were investigated in aqueous medium and the complex and its substituted products show remarkable anticancer property.
Collapse
Affiliation(s)
- Subhajit Mukherjee
- Department of Chemistry
- National Institute of Technology
- Durgapur-713209
- India
| | | | - Ishani Mitra
- Department of Chemistry
- National Institute of Technology
- Durgapur-713209
- India
| | - Rajnarayan Saha
- Department of Chemistry
- National Institute of Technology
- Durgapur-713209
- India
| | | | | | - Wolfgang Linert
- Institute of Applied Synthetic Chemistry
- Vienna University of Technology
- Vienna
- Austria
| | - Sankar Ch. Moi
- Department of Chemistry
- National Institute of Technology
- Durgapur-713209
- India
| |
Collapse
|
25
|
Ning FL, Wang F, Li ML, Yu ZS, Hao YZ, Chen SS. MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagn Pathol 2014; 9:143. [PMID: 25012722 PMCID: PMC4108001 DOI: 10.1186/1746-1596-9-143] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Accepted: 06/22/2014] [Indexed: 11/24/2022] Open
Abstract
Abstract Virtual Slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1793467320130186
Collapse
Affiliation(s)
| | | | | | | | | | - Shao-shui Chen
- Department of Oncology, Binzhou Medical College Affiliated Hospital, 661#, Yellow-River Second Street, 256603 Binzhou, Shandong Province, China.
| |
Collapse
|
26
|
Berger G, Leclercqz H, Derenne A, Gelbcke M, Goormaghtigh E, Nève J, Mathieu V, Dufrasne F. Synthesis and in vitro characterization of platinum(II) anticancer coordinates using FTIR spectroscopy and NCI COMPARE: A fast method for new compound discovery. Bioorg Med Chem 2014; 22:3527-36. [DOI: 10.1016/j.bmc.2014.04.017] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2013] [Revised: 02/26/2014] [Accepted: 04/10/2014] [Indexed: 01/15/2023]
|
27
|
MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. PLoS One 2014; 9:e94639. [PMID: 24722426 PMCID: PMC3983236 DOI: 10.1371/journal.pone.0094639] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Accepted: 03/18/2014] [Indexed: 11/30/2022] Open
Abstract
MicroRNAs (miRNAs) have been proven to play crucial roles in cancer, including tumor chemotherapy resistance and metastasis of non-small-cell lung cancer (NSCLC). TGFβ signal pathway abnormality is widely found in cancer and correlates with tumor proliferation, apoptosis and metastasis. Here, miR-17, 20a, 20b were detected down-regulated in A549/DDP cells (cisplatin resistance) compared with A549 cells (cisplatin sensitive). Over-expression of miR-17, 20a, 20b can not only decrease cisplatin-resistant but also reduce migration by inhibiting epithelial-to-mesenchymal transition (EMT) in A549/DDP cells. These functions of miR-17, 20a, 20b may be caused at least in part via inhibition of TGFβ signal pathway, as miR-17, 20a, 20b are shown to directly target and repress TGF-beta receptor 2 (TGFβR2) which is an important component of TGFβ signal pathway. Consequently, our study suggests that miRNA 17 family (including miR-17, 20a, 20b) can act as TGFβR2 suppressor for reversing cisplatin-resistant and suppressing metastasis in NSCLC.
Collapse
|
28
|
Wolf MA, Claudio PP. Benzyl isothiocyanate inhibits HNSCC cell migration and invasion, and sensitizes HNSCC cells to cisplatin. Nutr Cancer 2014; 66:285-94. [PMID: 24447182 DOI: 10.1080/01635581.2014.868912] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Metastasis and chemoresistance represent two detrimental events that greatly hinder the outcome for those suffering with head and neck squamous cell carcinoma (HNSCC). Herein, we investigated benzyl isothiocyanate's (BITC) ability to inhibit HNSCC migration and invasion and enhance chemotherapy. Our data suggests that treatment with BITC 1) induced significant reductions in the viability of multiple HNSCC cell lines tested (HN12, HN8, and HN30) after 24 and 48 h, 2) decreased migration and invasion of the HN12 cells in a dose dependent manner, and 3) inhibited expression and altered localization of the epithelial-mesenchymal transition (EMT) marker, vimentin. We also observed that a pretreatment of BITC followed by cisplatin treatment 1) induced a greater decrease in HN12, HN30, and HN8 cell viability and total cell count than either treatment alone and 2) significantly increased apoptosis when compared to either treatment alone. Taken together these data suggest that BITC has the capacity to inhibit processes involved in metastasis and enhance the effectiveness of chemotherapy. Consequently, the results indicate that further investigation, including in vivo studies, are warranted.
Collapse
Affiliation(s)
- M Allison Wolf
- a McKown Translational Genomic Research Institute and Department of Biochemistry and Microbiology, Joan C. Edwards School of Medicine , Marshall University, Huntington , West Virginia , USA
| | | |
Collapse
|
29
|
Stirland DL, Nichols JW, Miura S, Bae YH. Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release 2013; 172:1045-64. [PMID: 24096014 PMCID: PMC3889175 DOI: 10.1016/j.jconrel.2013.09.026] [Citation(s) in RCA: 166] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2013] [Revised: 09/07/2013] [Accepted: 09/25/2013] [Indexed: 11/23/2022]
Abstract
With countless research papers using preclinical models and showing the superiority of nanoparticle design over current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug carriers into the clinical setting is. This review article seeks to compare the preclinical and clinical results for Doxil®, PK1, Abraxane®, Genexol-PM®, Xyotax™, NC-6004, Mylotarg®, PK2, and CALAA-01. While not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common drugs used in chemotherapy. While not always available or comparable, effort was made to compare the pharmacokinetics, toxicity, and efficacy between the animal and human studies. Discussion is provided to suggest what might be causing the gap. Finally, suggestions and encouragement are dispensed for the potential that nano-sized drug carriers hold.
Collapse
Affiliation(s)
- Darren Lars Stirland
- University of Utah; Department of Bioengineering; College of Engineering; Salt Lake City; UT 84112; United States
| | - Joseph W. Nichols
- University of Utah; Department of Bioengineering; College of Engineering; Salt Lake City; UT 84112; United States
| | - Seiji Miura
- Fuji Research Laboratories, Pharmaceutical Division, Kowa Co. Ltd., 332–1 Ohnoshinden, Fuji, Shizuoka, Japan
- University of Utah, Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, Salt Lake City, UT 84112, United States
| | - You Han Bae
- University of Utah, Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, Salt Lake City, UT 84112, United States
| |
Collapse
|
30
|
Li Y, Li L, Guan Y, Liu X, Meng Q, Guo Q. MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochem Biophys Res Commun 2013; 440:604-10. [PMID: 24099768 DOI: 10.1016/j.bbrc.2013.09.111] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2013] [Accepted: 09/22/2013] [Indexed: 12/22/2022]
Abstract
MicroRNAs (miRNAs) have emerged to play important roles in tumorigenesis and drug resistance of human cancer. Fewer studies were explored the roles of miR-92b on human lung cancer cell growth and resistance to cisplatin (CDDP). In this paper, we utilized real-time PCR to verify miR-92b was significantly up-regulated in non-small cell lung cancer (NSCLC) tissues compared to matched adjacent normal tissues. In vitro assay demonstrated that knock-down of miR-92b inhabits cell growth and sensitized the A549/CDDP cells to CDDP. Furthermore, we found miR-92b could directly target PTEN, a unique tumor suppressor gene, which was downregulated in lung cancer tissues compared to the matched adjacent normal tissues. These data indicate that the miR-92b play an oncogene roles by regulates cell growth, cisplatin chemosensitivity phenotype, and could serve as a novel potential maker for NSCLC therapy.
Collapse
Affiliation(s)
- Yan Li
- Department of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan University, Jinan, Shandong 250117, PR China
| | | | | | | | | | | |
Collapse
|
31
|
De Carlo F, Witte TR, Hardman WE, Claudio PP. Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy. PLoS One 2013; 8:e69760. [PMID: 23874993 PMCID: PMC3713061 DOI: 10.1371/journal.pone.0069760] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Accepted: 06/12/2013] [Indexed: 01/29/2023] Open
Abstract
Colorectal cancer is the third leading cause of cancer-related death in the western world. In vitro and in vivo experiments showed that omega-3 polyunsaturated fatty acids (n-3 PUFAs) can attenuate the proliferation of cancer cells, including colon cancer, and increase the efficacy of various anticancer drugs. However, these studies address the effects of n-3 PUFAs on the bulk of the tumor cells and not on the undifferentiated colon cancer stem-like cells (CSLCs) that are responsible for tumor formation and maintenance. CSLCs have also been linked to the acquisition of chemotherapy resistance and to tumor relapse. Colon CSLCs have been immunophenotyped using several antibodies against cellular markers including CD133, CD44, EpCAM, and ALDH. Anti-CD133 has been used to isolate a population of colon cancer cells that retains stem cells properties (CSLCs) from both established cell lines and primary cell cultures. We demonstrated that the n-3 PUFA, eicosapentaenoic acid (EPA), was actively incorporated into the membrane lipids of COLO 320 DM cells. 25 uM EPA decreased the cell number of the overall population of cancer cells, but not of the CD133 (+) CSLCs. Also, we observed that EPA induced down-regulation of CD133 expression and up-regulation of colonic epithelium differentiation markers, Cytokeratin 20 (CK20) and Mucin 2 (MUC2). Finally, we demonstrated that EPA increased the sensitivity of COLO 320 DM cells (total population) to both standard-of-care chemotherapies (5-Fluorouracil and oxaliplatin), whereas EPA increased the sensitivity of the CD133 (+) CSLCs to only 5-Fluorouracil.
Collapse
Affiliation(s)
- Flavia De Carlo
- Department of Biochemistry and Microbiology, Joan Edwards School of Medicine, Marshall University, Huntington, West Virginia, United States of America
- McKown Translational Genomic Research Institute, Joan Edwards School of Medicine Marshall University, Huntington, West Virginia, United States of America
| | - Theodore R. Witte
- Department of Biochemistry and Microbiology, Joan Edwards School of Medicine, Marshall University, Huntington, West Virginia, United States of America
- McKown Translational Genomic Research Institute, Joan Edwards School of Medicine Marshall University, Huntington, West Virginia, United States of America
| | - W. Elaine Hardman
- Department of Biochemistry and Microbiology, Joan Edwards School of Medicine, Marshall University, Huntington, West Virginia, United States of America
- McKown Translational Genomic Research Institute, Joan Edwards School of Medicine Marshall University, Huntington, West Virginia, United States of America
| | - Pier Paolo Claudio
- Department of Biochemistry and Microbiology, Joan Edwards School of Medicine, Marshall University, Huntington, West Virginia, United States of America
- McKown Translational Genomic Research Institute, Joan Edwards School of Medicine Marshall University, Huntington, West Virginia, United States of America
- Department of Surgery, Joan Edwards School of Medicine, Marshall University, Huntington, West Virginia, United States of America
- * E-mail:
| |
Collapse
|
32
|
Zalba S, Garrido MJ. Liposomes, a promising strategy for clinical application of platinum derivatives. Expert Opin Drug Deliv 2013; 10:829-44. [DOI: 10.1517/17425247.2013.778240] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
33
|
Sarmah A, Roy RK. Understanding the preferential binding interaction of aqua-cisplatins with nucleobase guanine over adenine: a density functional reactivity theory based approach. RSC Adv 2013. [DOI: 10.1039/c2ra23223e] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
34
|
Biersack B, Dietrich A, Zoldakova M, Kalinowski B, Paschke R, Schobert R, Mueller T. Lipophilic Pt(II) complexes with selective efficacy against cisplatin-resistant testicular cancer cells. J Inorg Biochem 2011; 105:1630-7. [PMID: 22071088 DOI: 10.1016/j.jinorgbio.2011.08.028] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2011] [Revised: 08/01/2011] [Accepted: 08/22/2011] [Indexed: 12/01/2022]
Abstract
A series of dichloridoplatinum(II) complexes with selective and high cytotoxicity [IC(90)(96h)≤3 μM] against cisplatin-resistant 1411HP testicular cancer cells were identified. They bear stationary 6-aminomethylnicotinate or 2,4-diaminobutyrate ligands esterified with lipophilic terpenyl residues, i.e., (-)/(+)-menthyl, (+)-cedrenyl, (-)-menthoxypropyl, or with a decyl-tethered 1,1,2-triphenylethene. They accumulated to a larger extent in 1411HP cells than in cells of the cisplatin-sensitive H12.1 germ cell tumour. Their mechanism of apoptosis induction differed from that of cisplatin by being independent of p53 and of caspase-3 activation and by an early loss of the mitochondrial membrane potential. The new complexes are promising candidates for the treatment of cisplatin-resistant testicular tumours.
Collapse
Affiliation(s)
- Bernhard Biersack
- Organic Chemistry Laboratory, University Bayreuth, Bayreuth, Germany
| | | | | | | | | | | | | |
Collapse
|
35
|
Affiliation(s)
- Vishnu Sresht
- Department of Chemical Engineering, Indian Institute of Technology Bombay, Powai, Mumbai 400 076, India
| | - Jayesh R. Bellare
- Department of Chemical Engineering, Indian Institute of Technology Bombay, Powai, Mumbai 400 076, India
| | - Santosh K. Gupta
- Department of Chemical Engineering, Indian Institute of Technology Bombay, Powai, Mumbai 400 076, India
| |
Collapse
|
36
|
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer 2011; 104:593-8. [PMID: 21285987 PMCID: PMC3049602 DOI: 10.1038/bjc.2011.6] [Citation(s) in RCA: 270] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Background: On the basis of preclinical studies of NC-6004, a cisplatin-incorporated micellar formulation, we hypothesised that NC-6004 could show lower toxicity than cisplatin and show greater anti-tumour activity in phase I study. Methods: A total of 17 patients were recruited in a range of advanced solid tumour types. NC-6004 was administered intravenously (i.v.) every 3 weeks. The dose escalation started at 10 mg m−2 and was increased up to 120 mg m−2 according to the accelerated titration method and modified Fibonacci method. Results: One dose-limiting toxicity (DLT) occurred in a patient who was given 90 mg m−2 of NC-6004, otherwise any significant cisplatin-related toxicity was not observed or generally mild toxicity was observed. Despite the implementation of post-hydration and pre-medication regimen, renal impairment and hypersensitivity reactions still developed at 120 mg m−2, which led to the conclusion that the maximum tolerated dose was 120 mg m−2, and the recommended dose was 90 mg m−2, although DLT was not defined as per protocol. Stable disease was observed in seven patients. The maximum concentration and area under the concentration–time curve of ultrafilterable platinum at 120 mg m−2 NC-6004 were 34-fold smaller and 8.5-fold larger, respectively, than those for cisplatin. Conclusion: The delayed and sustained release of cisplatin after i.v. administration contributes to the low toxicity of NC-6004.
Collapse
|
37
|
Wang Q, You T, Yuan D, Han X, Hong X, He B, Wang L, Tong X, Tao L, Harris AL. Cisplatin and oxaliplatin inhibit gap junctional communication by direct action and by reduction of connexin expression, thereby counteracting cytotoxic efficacy. J Pharmacol Exp Ther 2010; 333:903-11. [PMID: 20215407 DOI: 10.1124/jpet.109.165274] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Cisplatin [cis-diamminedichloroplatinum(II)]/oxaliplatin [1,2-diamminocyclohexane(trans-1)oxolatoplatinum(II)] toxicity is enhanced by functional gap junctions between treated cells, implying that inhibition of gap junctions may decrease cytotoxic activity of these platinum-based agents. This study investigates the effect of gap junction modulation by cisplatin/oxaliplatin on cytotoxicity in a transformed cell line. The effects were explored using junctional channels expressed in transfected HeLa cells and purified hemichannels. Junctional channels showed a rapid, dose-dependent decrease in dye coupling with exposure to cisplatin/oxaliplatin. With longer exposure, both compounds also decreased connexin expression. Both compounds inhibit the activity of purified connexin hemichannels, over the same concentration range that they inhibit junctional dye permeability, demonstrating that inhibition occurs by direct interaction of the drugs with connexin protein. Cisplatin/oxaliplatin reduced the clonogenic survival of HeLa cells at low density and high density in a dose-dependent manner, but to a greater degree at high density, consistent with a positive effect of gap junctional intercellular communication (GJIC) on cytotoxicity. Reduction of GJIC by genetic or pharmacological means decreased cisplatin/oxaliplatin toxicity. At low cisplatin/oxaliplatin concentrations, where effects on connexin channels are minimal, the toxicity increased with increased cell density. However, higher concentrations strongly inhibited GJIC, and this counteracted the enhancing effect of greater cell density on toxicity. The present results indicate that inhibition of GJIC by cisplatin/oxaliplatin decreases their cytotoxicity. Direct inhibition of GJIC and reduction of connexin expression by cisplatin/oxaliplatin may thereby compromise the effectiveness of these compounds and be a factor in the development of resistance to this class of chemotherapeutic agents.
Collapse
Affiliation(s)
- Qin Wang
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, People's Republic of China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Gatti L, Perego P, Leone R, Apostoli P, Carenini N, Corna E, Allievi C, Bastrup U, De Munari S, Di Giovine S, Nicoli P, Grugni M, Natangelo M, Pardi G, Pezzoni G, Singer JW, Zunino F. Novel Bis-platinum Complexes Endowed with an Improved Pharmacological Profile. Mol Pharm 2009; 7:207-16. [DOI: 10.1021/mp900211j] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Laura Gatti
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Paola Perego
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Roberto Leone
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Piero Apostoli
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Nives Carenini
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Elisabetta Corna
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Cecilia Allievi
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Ulla Bastrup
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Sergio De Munari
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Stefano Di Giovine
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Paola Nicoli
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Mario Grugni
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Marco Natangelo
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Gianluca Pardi
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Gabriella Pezzoni
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Jack W. Singer
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| | - Franco Zunino
- Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto di Farmacologia, Università di Verona, Verona, Italy, Istituto di Medicina del Lavoro, Università di Brescia, Brescia, Italy, and Cell Therapeutics Inc., via Ariosto 23, Bresso, Milan, Italy
| |
Collapse
|
39
|
Walker JM, McEwan A, Pycko R, Tassotto ML, Gottardo C, Th'ng J, Wang R, Spivak GJ. [Tris(pyrazolyl)methane]ruthenium Complexes Capable of Inhibiting Cancer Cell Growth. Eur J Inorg Chem 2009. [DOI: 10.1002/ejic.200900766] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
40
|
Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S, Ma D. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 2008; 271:260-71. [PMID: 18657898 DOI: 10.1016/j.canlet.2008.06.012] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2008] [Revised: 03/31/2008] [Accepted: 06/11/2008] [Indexed: 10/21/2022]
Abstract
PURPOSE The aim of this study was to explore role of PTEN gene in chemosensitivity to cisplatin in human ovarian cancer cells and related mechanisms. METHOD A PTEN-targeted short hairpin RNA (shRNA) expression vector and a wild-type sense PTEN plasmid were constructed, human ovarian cisplatin-sensitive cancer cell line OV2008 and its resistant variant C13 * cells were transfected with PTEN shRNA or wild-type PTEN plasmid, respectively, and cells were then treated with cisplatin. Next, AKT activity was regulated with co-transfection of antisense or sense AKT plasmid in OV2008 /PTENshRNA cells or C13 */p-PTEN cells, respectively. Effects of transfection of above vectors on cell growth, apoptosis and expression of PTEN and AKT were evaluated. RESULTS Expression of PTEN in OV2008 cells was significantly higher than that in C13 * cells. Transfection of PTEN shRNA into OV2008 cells remarkably down-regulated expression of PTEN and up-regulated expression of phospho-AKT protein, with transfected cells being resistant to cisplatin. Overexpression of PTEN by transfection with sense PTEN obviously enhanced cisplatin-induced apoptosis of C13 * cells. Furthermore, decreased AKT activity could increase cisplatin-induced apoptosis in OV2008/PTENshRNA cells; while, transfection of pcDNA3.1-AKT plasmid into C13 */p-PTEN cells resulted in increased activity of AKT, with cisplatin-induced apoptosis being inhibited significantly. CONCLUSIONS PTEN might reverse chemoresistance to cisplatin in human ovarian cancer cells through inactivation of the PI3K/AKT cell survival pathway and may serve as a potential molecular target for the treatment of chemoresistant ovarian cancer.
Collapse
Affiliation(s)
- HuiJuan Wu
- Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Fisher DM, Fenton RR, Aldrich-Wright JR. In vivo studies of a platinum(ii) metallointercalator. Chem Commun (Camb) 2008:5613-5. [DOI: 10.1039/b811723c] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
43
|
Briasoulis E, Fountzilas G, Bamias A, Dimopoulos MA, Xiros N, Aravantinos G, Samantas E, Kalofonos H, Makatsoris T, Mylonakis N, Papakostas P, Skarlos D, Varthalitis I, Pavlidis N. Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study. Cancer Chemother Pharmacol 2007; 62:277-84. [PMID: 17901952 DOI: 10.1007/s00280-007-0604-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2007] [Accepted: 09/10/2007] [Indexed: 11/30/2022]
Abstract
BACKGROUND Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan-oxaliplatin combination (IROX regimen) in previously untreated patients with non-favorable subsets of unknown primary carcinomas. METHODS This was a multicenter phase-II trial. Protocol treatment consisted of oxaliplatin 80 mg/m(2) followed by irinotecan 160 mg/m(2) administered every 3 weeks. The primary end points were response rate and toxicity, and secondary end points were time to progression and survival. RESULTS Forty-seven patients with liver, bone or multiple visceral metastases entered into the trial and received a median 6 chemotherapy cycles (1-11). The regimen was very well tolerated with one febrile neutropenia case and six cases with diarrhea grade 3 (16%). In intent-to-treat analysis the tumor response rate was 13% (95% CI = 4.8-25.7%) and 12 patients (27%, 95%CI 13.9-40.4%) had at least 4 months' duration of disease stabilization. The median time to progression was 2.7 months and the median survival was 9.5 months, with 40% of patients alive at 1 year. CONCLUSIONS The IROX regimen demonstrated similar efficacy and a favorable toxicity profile compared to other more toxic chemotherapy combinations in patients with poor-prognosis CUP.
Collapse
|
44
|
Loh GW, Ting LSL, Ensom MHH. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin Pharmacokinet 2007; 46:471-94. [PMID: 17518507 DOI: 10.2165/00003088-200746060-00002] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Despite evidence in the literature suggesting that a strong correlation exists between the pharmacokinetic parameters and pharmacodynamic effect of anticancer agents, many of these agents are still dosed by body surface area. Therapeutic drug monitoring with the aim of pharmacokinetic-guided dosing would not only maintain target concentrations associated with efficacy but may potentially minimise the likelihood of dose-related systemic toxicities. The pharmacokinetic parameter that displays the best correlation with the pharmacodynamics of anticancer drugs is the area under the plasma concentration-time curve (AUC). However, accurate determination of the AUC requires numerous blood samples over an extended interval, which is not feasible in clinical practice. Therefore, limited sampling strategies (LSSs) have been proposed as a means to accurately and precisely estimate pharmacokinetic parameters with a minimal number of blood samples. LSSs have been developed for many drugs, particularly ciclosporin and other immunosuppressants, as well as for certain anticancer drugs. This systematic review evaluates LSSs developed for the platinum compounds and categorises 18 pertinent citations according to criteria adapted from the US Preventive Services Task Force. Thirteen citations (four level I, six level II-1, three level II-2) pertained to LSSs for carboplatin, four citations (one level II-1, one level II-2, two level III) to cisplatin LSSs, and one citation (level II-2) to nedaplatin. Based on the current evidence, it appears that LSSs may be useful for pharmacokinetic-guided dosage adjustments of carboplatin in both adults and children with cancer. Although some validation studies suggest that LSSs can be extended to different cancer populations or different chemotherapy regimens, other studies dispute this finding. Although the use of LSSs to predict the pharmacokinetic parameters of cisplatin and nedaplatin appear promising, the quality of evidence from published studies does not support routine implementation at this time.LSSs represent one approach in which clinicians can make specific dosage adjustments for individual patients to optimise outcomes. However, the limitations of these strategies must also be taken into consideration. There is also a need for prospective studies to demonstrate that application of LSSs for platinum agents ultimately improves patient response and decreases systemic toxicities.
Collapse
Affiliation(s)
- Gabriel W Loh
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | | | | |
Collapse
|
45
|
Mantri Y, Lippard SJ, Baik MH. Bifunctional binding of cisplatin to DNA: why does cisplatin form 1,2-intrastrand cross-links with ag but not with GA? J Am Chem Soc 2007; 129:5023-30. [PMID: 17402732 PMCID: PMC2495024 DOI: 10.1021/ja067631z] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The bifunctional binding of the anticancer drug cisplatin to two adjacent nucleobases in DNA is modeled using density functional theory. Previous experimental studies revealed that cisplatin binding to adjacent guanine and adenine is sensitive to nucleobase sequence. Whereas AG 1,2-intrastrand cross-links are commonly observed, the analogous GA adducts are not known. This study focuses on understanding this directional preference by constructing a full reaction profile using quantum chemical simulation methods. Monofunctional and bifunctional cisplatin adducts were generated, and the transition states that connect them were located for the dinucleotides d(pApG) and d(pGpA), assuming that initial platination takes place at the guanine site. Our computer simulations reveal a significant kinetic preference for formation of the AG over the GA adduct. The activation free energies of approximately 23 kcal/mol for AG and approximately 32 kcal/mol for GA suggest that bifunctional closure is approximately 6 orders of magnitude faster for AG than for GA. A strong hydrogen bond between one of the ammine ligands of cisplatin and the 5' phosphate group of the DNA backbone is responsible for the stabilization of the transition state that affords the AG adduct. This interaction is absent in the transition state that leads to the GA adduct because the right-handed helix of the DNA backbone places the phosphate out of reach for the ammine ligand. We found only an insignificant thermodynamic difference between AG and GA adducts and conclude that the preference of AG over GA binding is largely under kinetic control. The puckering of the deoxyribose ring plays an important role in determining the energetics of the bifunctional platination products. Whereas the 3'-nucleoside remains in the native C2'-endo/C3'-exo form of B-DNA, the deoxyribose of the 5'-nucleoside always adopts the C2'-exo/C3'-endo puckering in our simulations. A detailed analysis of the energies and structures of the bifunctional adducts revealed that the observed sugar puckering patterns are necessary for platinum to bind in a relaxed coordination geometry.
Collapse
Affiliation(s)
- Yogita Mantri
- Department of Chemistry and School of Informatics, Indiana University, Bloomington, Indiana 47405, USA
| | | | | |
Collapse
|
46
|
Hannon MJ, Green PS, Fisher DM, Derrick PJ, Beck JL, Watt SJ, Ralph SF, Sheil MM, Barker PR, Alcock NW, Price RJ, Sanders KJ, Pither R, Davis J, Rodger A. An Estrogen–Platinum Terpyridine Conjugate: DNA and Protein Binding and Cellular Delivery. Chemistry 2006; 12:8000-13. [PMID: 16881027 DOI: 10.1002/chem.200501012] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
A platinum metal complex in which terpyridine joins estradiol (via an ethynyl link) to a platinum with a labile ligand (chloride) has been designed, synthesised and its X-ray crystal structure determined. The aim of this work was to link a targeting motif (in this case estrogen) to a metal-based biomolecule recognition unit (the platinum moiety). The target molecule: 17alpha-[4'-ethynyl-2,2':6',2'-terpyridine]-17beta-estradiol platinum(II) chloride (PtEEtpy) has been shown to bind to both human and bovine serum albumin (SA) and to DNA. FTICR mass spectrometry shows that the bimolecular units are in each case linked through coordination to the platinum with displacement of the chloride ligand. Circular dichroism indicates that a termolecular entity involving PtEEtpy, SA and DNA is formed. A range of electrospray mass spectrometry experiments showed that the PtEEtpy complex breaks and forms coordination bonds relatively easily. A whole cell estrogen receptor assay in an estrogen receptor positive cell (MCF-7) confirms binding of both EEtpy and PtEEtpy to the estrogen receptor in cells. The work demonstrates the concept of linking a targeting moiety (in this case estrogen) to a DNA binding agent.
Collapse
Affiliation(s)
- Michael J Hannon
- Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Synthesis, characterization and biological activity of platinum(II) complexes with l- and d-ornithine ligands. Inorganica Chim Acta 2006. [DOI: 10.1016/j.ica.2006.06.038] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
48
|
Khlebnikova TS, Merkushin IV, Lakhvich FA. Platinum(II) cationic complexes with derivatives of 2-acyl-1,3-cyclopentanedions. RUSS J GEN CHEM+ 2006. [DOI: 10.1134/s107036320605001x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
49
|
Jerremalm E, Wallin I, Yachnin J, Ehrsson H. Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate. Eur J Pharm Sci 2006; 28:278-83. [PMID: 16621479 DOI: 10.1016/j.ejps.2006.03.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2005] [Revised: 03/01/2006] [Accepted: 03/06/2006] [Indexed: 11/26/2022]
Abstract
Oxaliplatin undergoes extensive non-enzymatic chemical transformation in the body. Complexes with sulphur-containing compounds have previously been found in plasma from patients treated with oxaliplatin. We have studied the kinetics for the reactions between oxaliplatin and cysteine, methionine, and glutathione, by determination of the degradation of oxaliplatin using liquid chromatography with UV-detection. We also studied the degradation of oxaliplatin in plasma ultrafiltrate (PUF). For the degradation of oxaliplatin in the presence of glutathione, methionine, and cysteine, the second-order rate constants were 4.7M(-1)min(-1) (95% confidence interval [C.I.], 4.4-5.0M(-1)min(-1)), 5.5M(-1)min(-1) (95% C.I., 5.2-5.7M(-1)min(-1)), and 15M(-1)min(-1) (95% C.I., 14-17M(-1)min(-1)), respectively. The reaction rate was much faster than previously reported kinetics for cisplatin. The degradation rate of oxaliplatin in PUF was biphasic. The rate constant for the first phase varied from 9.5x10(-3) to 0.13min(-1) and for the second phase from (1.7 to 1.8)x10(-3)min(-1) in PUF from five healthy volunteers. The first hours of the degradation of oxaliplatin in PUF are accounted for by the degradation of oxaliplatin in a cocktail of sodium chloride and sulphur-containing compounds at physiological plasma concentrations. In conclusion, the rate of the reaction of oxaliplatin with three sulphur-containing compounds was faster for oxaliplatin than what is previously known for cisplatin. This may be important with respect to differences in the cellular effects of cisplatin and oxaliplatin treatment.
Collapse
Affiliation(s)
- Elin Jerremalm
- Karolinska Pharmacy, Karolinska University Hospital, S-171 76 Stockholm, Sweden.
| | | | | | | |
Collapse
|
50
|
Abstract
Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER-2) protein, the mediator of an aggressive breast cancer phenotype. Trastuzumab has an important role in the treatment of metastatic breast cancer (MBC) where it improves multiple endpoints, including overall survival. More recently, striking activity is also seen in non-MBC, with substantial benefits seen in both the neoadjuvant and adjuvant settings. Experimental data has identified synergistic therapeutic effects of platinum containing chemotherapeutic regimens when combined with trastuzumab. We review the pre-clinical and rapidly evolving clinical evidence supporting platinum and trastuzumab combinations for HER-2-positive breast cancer.
Collapse
|